Skip to main content
. 2021 Aug 6;13:6141–6155. doi: 10.2147/CMAR.S312621

Figure 4.

Figure 4

TNRC6C-AS1 interacts with and downregulates miR-513c-5p. (A) The putative binding site of TNRC6C-AS1 and miR-513c-5p is shown. (B) Luciferase activity was measured in SW579 and TPC-1 cells co-transfected with wild type (TNRC6C-AS1-Wt) or mutant (TNRC6C-AS1-Mut) TNRC6C-AS1 and miR-513c-5p using the luciferase reporter assay. **P < 0.001 vs miR-NC. (C) Anti-AGO2 RIP was performed in SW579 and TPC-1 cells transiently overexpressing miR-513c-5p followed by qRT-PCR to detect TNRC6C-AS1 associated with miR-513c-5p. **P < 0.001. (D) The expression level of miR-513c-5p was detected by qRT-PCR in THCA tissues and paired adjacent normal tissues. (E) Pearson correlation analysis of the correlation between TNRC6C-AS1 and miR-513c-5p in THCA tissues. (F) The expression level of miR-513c-5p was measured by qRT-PCR in the human thyroid follicular epithelial cell line (Nthy-ori 3–1) and THCA cell lines (TPC-1 and SW579). **P < 0.001 vs Nthy-ori 3–1. (G) The expression level of TNRC6C-AS1 and miR-513c-5p were measured by qRT-PCR in SW579 and TPC-1 cells transfected with si-lnc or miR-513c-5p inhibitor. si-lnc, Silencing TNRC6C-AS1. **P < 0.001 vs blank; ## P < 0.001 vs si-lnc+inhibitor.

Abbreviation: si-lnc-NC, negative control of si-lnc.